comparemela.com

Latest Breaking News On - Silverarc capital management - Page 2 : comparemela.com

Bain Capital Life Sciences Investors LLC Purchases 2,359,793 Shares of Annexon, Inc. (NASDAQ:ANNX)

Bain Capital Life Sciences Investors LLC grew its position in shares of Annexon, Inc. (NASDAQ:ANNX – Free Report) by 41.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,061,719 shares of the company’s stock after buying an additional 2,359,793 shares during the period. […]

United-states
America
Silverarc-capital-management
Needham-company
Jpmorgan-chase-co
Annexon-inc
Nasdaq
Bain-capital-life-sciences-investors
Sectoral-asset-management-inc
Exchange-commission
Annexon-company-profile

Bain Capital Life Sciences Investors LLC Purchases 2,359,793 Shares of Annexon, Inc. (NASDAQ:ANNX)

Bain Capital Life Sciences Investors LLC grew its position in shares of Annexon, Inc. (NASDAQ:ANNX – Free Report) by 41.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,061,719 shares of the company’s stock after buying an additional 2,359,793 shares during the period. […]

United-states
America
Nasdaq
Needham-company
Jpmorgan-chase-co
Annexon-inc
Silverarc-capital-management
Kennedy-capital-management
Tower-research-capital
Sg-americas-securities
Exchange-commission

Cyrus Harmon Sells 5,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) Director Cyrus Harmon sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $10.93, for a total value of $54,650.00. Following the completion of the transaction, the director now owns 786,283 shares […]

Cyrus-harmon
Clarivest-asset-management
Silverarc-capital-management
Goldman-sachs-group
Olema-pharmaceuticals
Quarter-for-olema-pharmaceuticals
Victory-capital-management-inc
News-ratings-for-olema-pharmaceuticals-daily
Nasdaq
Vivo-capital
Olema-pharmaceuticals-inc
Institutional-investors-weigh-in-on-olema-pharmaceuticals

Rhenman & Partners Asset Management AB Has $2.04 Million Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Rhenman & Partners Asset Management AB decreased its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 65.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 112,741 shares of the company’s stock after selling 217,894 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Pliant Therapeutics were worth $2,042,000 […]

United-states
Canada
Exchange-commission
Needham-company
Silverarc-capital-management
Vanguard-group-inc
Pliant-therapeutics-inc
Royal-bank
Barclays-plc
Holdings-channel
Citigroup

DLD Asset Management LP Acquires New Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

DLD Asset Management LP acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,000 shares of the company’s stock, valued at approximately $223,000. DLD Asset Management LP owned about […]

Robertw-baird
York-mellon-corp
Praxis-precision-medicines-inc
Nasdaq
Jefferies-financial-group
Exchange-commission
Citigroup-inc
Acuta-capital-partners
Silverarc-capital-management
Praxis-precision-medicines
Free-report

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.